BioLife Sciences Inc

Healthcare US BLFE

0.0001USD
-(-%)

Last update at 2025-06-16T13:30:00Z

Day Range

0.00010.0001
LowHigh

52 Week Range

-0.0002
LowHigh

Fundamentals

  • Previous Close 0.0001
  • Market Cap0.32M
  • Volume0
  • P/E Ratio-
  • Dividend Yield-%
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.04

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2021-11-30 2020-11-30 2007-11-30 2006-11-30 2005-11-30
Type yearly yearly yearly yearly yearly
Date 2021-11-30 2020-11-30 2007-11-30 2006-11-30 2005-11-30
Income before tax - - -2.04605M -0.29119M -0.47948M
Minority interest - - - - -
Net income - - -2.04605M -0.29119M -0.47948M
Selling general administrative - - - - -
Selling and marketing expenses - - - - -
Gross profit - - 1.57M 1.13M 0.00589M
Reconciled depreciation - - - - -
Ebit -0.41986M -1.26727M 1.44M -0.09601M -0.52681M
Ebitda - - 1.71M 0.07M -0.57415M
Depreciation and amortization - - 0.27M 0.17M -0.04734M
Non operating income net other - - - - -
Operating income - - 0.04M 0.13M -0.52681M
Other operating expenses - - 8.56M 6.44M 0.53M
Interest expense 0.00000M 0.00000M 0.69M 0.43M -
Tax provision - - - - -
Interest income - - - - -
Net interest income - - - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - 2.09M 0.31M -
Total revenue - - 8.60M 6.46M 0.00589M
Total operating expenses - - 1.53M 1.11M 0.53M
Cost of revenue - - 7.04M 5.33M -
Total other income expense net - - -1.39715M 0.11M 0.05M
Discontinued operations - - - - -
Net income from continuing ops - - - - -
Net income applicable to common shares -0.45687M -1.26774M - - -
Preferred stock and other adjustments - - - - -
Breakdown 2021-11-30 2020-11-30 2019-11-30 2007-11-30 2006-11-30
Type yearly yearly yearly yearly yearly
Date 2021-11-30 2020-11-30 2019-11-30 2007-11-30 2006-11-30
Total assets - - 0.00002M 3.76M 3.47M
Intangible assets - - - 1.48M 1.73M
Earning assets - - - - -
Other current assets - - - 0.43M 0.34M
Total liab - - 0.00117M 3.70M 3.22M
Total stockholder equity - - -0.00115M 0.06M 0.25M
Deferred long term liab - - - - -
Other current liab 0.09M 0.08M 0.00117M 0.32M 0.25M
Common stock 0.00571M 0.00554M - 0.03M 0.01M
Capital stock - - - - -
Retained earnings -1.72576M -1.26889M -0.00115M -3.88487M -1.83882M
Other liab - - - - -
Good will - - - 0.24M 0.27M
Other assets - - - - -
Cash - - 0.00002M 0.40M 0.07M
Cash and equivalents - - - - -
Total current liabilities 1.07M 0.84M 0.00117M 3.50M 0.93M
Current deferred revenue - - - - -
Net debt - - -0.00002M 2.26M 2.34M
Short term debt - - - 2.45M 0.34M
Short long term debt - - - - -
Short long term debt total - - - 2.66M 2.42M
Other stockholder equity -0.00673M -0.03586M - 7.90M 2.13M
Property plant equipment 0.12M 0.20M - - -
Total current assets 0.08M 0.07M 0.00002M 1.38M 1.11M
Long term investments - - - - -
Net tangible assets -0.88033M -0.68958M - - -
Short term investments - - - 0.00442M 0.08M
Net receivables - - - 0.49M 0.59M
Long term debt - - - - -
Inventory - - - 0.05M 0.02M
Accounts payable 0.58M 0.49M - 0.72M 0.34M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - -0.03619M -0.05596M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - 0.57M 0.24M
Deferred long term asset charges - - - - -
Non current assets total - - - 2.38M 2.37M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2021-11-30 2020-11-30 2007-11-30 2006-11-30 2005-11-30
Type yearly yearly yearly yearly yearly
Date 2021-11-30 2020-11-30 2007-11-30 2006-11-30 2005-11-30
Investments - - - - -
Change to liabilities 0.21M 0.30M - - -
Total cashflows from investing activities - -0.00096M - - -
Net borrowings 0.07M 0.88M - - -
Total cash from financing activities 0.07M 0.99M 0.58M 0.50M 1.28M
Change to operating activities -0.02363M -0.03587M - - -
Net income -0.45687M -1.26774M -2.04605M -0.29119M -0.47948M
Change in cash -0.01766M 0.03M 0.33M -1.11622M 1.19M
Begin period cash flow - 0.40M 0.07M 1.19M -
End period cash flow - - 0.40M 0.07M 1.19M
Total cash from operating activities -0.10655M -1.00040M -0.28542M -0.03766M -0.05302M
Issuance of capital stock - - - - -
Depreciation - - 0.27M 0.17M -
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - 0.00002M - - -
Change to account receivables - - - - -
Sale purchase of stock - - - - -
Other cashflows from financing activities - 0.88M 0.23M -1.57925M 1.26M
Change to netincome 0.16M 0.00432M - - -
Capital expenditures 0.00000M 0.00096M 0.00000M 0.02M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital - - 0.57M -0.01153M -0.03897M
Stock based compensation - - - - -
Other non cash items - - 0.92M 0.10M 0.47M
Free cash flow - - -0.28542M -0.06241M -0.05302M

Peer Comparison

Sector: Healthcare Industry: Medical Instruments & Supplies

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BLFE
BioLife Sciences Inc
- -% 0.0001 - - 0.001 - 0.13 9.15
ISRG
Intuitive Surgical Inc
-2.375 0.46% 516.66 73.05 61.73 19.15 10.25 18.41 59.92
ESLOY
Essilor International SA
-0.86 0.62% 138.71 35.39 24.81 3.63 2.20 4.00 16.25
ESLOF
EssilorLuxottica Société anonyme
-0.25 0.09% 277.00 35.71 25.13 3.62 2.23 4.00 16.25
BDX
Becton Dickinson and Company
-0.81 0.47% 171.29 37.72 15.92 3.25 2.49 4.08 17.10

Reports Covered

Stock Research & News

Profile

BioLife Sciences Inc. develops, licenses, and commercializes products and technologies for the healthcare, beauty, and food and beverage industries. It also offers orthomolecular products. The company is based in Henderson, Nevada.

BioLife Sciences Inc

2831 Saint Rose Parkway, Henderson, NV, United States, 89052

Key Executives

Name Title Year Born
Mr. Justin De Four Founder, CEO & Chairman 1990
Mr. Colton De Gooyer Director of Operations NA
Ms. Nika Jaksic COO & Director 1980
Ms. Nika Jaksic COO & Director 1981

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.